Networks of face-to-face social contacts in Niakhar, Senegal.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 25 09 2018
accepted: 15 07 2019
entrez: 7 8 2019
pubmed: 7 8 2019
medline: 11 3 2020
Statut: epublish

Résumé

We present the first analysis of face-to-face contact network data from Niakhar, Senegal. Participants in a cluster-randomized influenza vaccine trial were interviewed about their contact patterns when they reported symptoms during their weekly household surveillance visit. We employ a negative binomial model to estimate effects of covariates on contact degree. We estimate the mean contact degree for asymptomatic Niakhar residents to be 16.5 (95% C.I. 14.3, 18.7) in the morning and 14.8 in the afternoon (95% C.I. 12.7, 16.9). We estimate that symptomatic people make 10% fewer contacts than asymptomatic people (95% C.I. 5%, 16%; p = 0.006), and those aged 0-5 make 33% fewer contacts than adults (95% C.I. 29%, 37%; p < 0.001). By explicitly modelling the partial rounding pattern observed in our data, we make inference for both the underlying (true) distribution of contacts as well as for the reported distribution. We created an estimator for homophily by compound (household) membership and estimate that 48% of contacts by symptomatic people are made to their own compound members in the morning (95% CI, 45%, 52%) and 60% in the afternoon/evening (95% CI, 56%, 64%). We did not find a significant effect of symptom status on compound homophily. We compare our findings to those from other countries and make design recommendations for future surveys.

Identifiants

pubmed: 31386686
doi: 10.1371/journal.pone.0220443
pii: PONE-D-18-27976
pmc: PMC6684077
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0220443

Subventions

Organisme : NIGMS NIH HHS
ID : U01 GM070749
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM111274
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP000174
Pays : United States

Déclaration de conflit d'intérêts

GEP is currently employed by the Emmes Company. The Emmes Company was contracted to perform data cleaning and data analysis of the clinical trial data (but not the social contact network data) for this study before GEP joined the Emmes Company (in October 2015). After GEP joined the Emmes Company, the sole support from Emmes for this social network analysis manuscript was in the form of salary support for GEP. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The other authors have declared no COI.

Références

Int J Infect Dis. 2011 Aug;15(8):e510-3
pubmed: 21737332
Cell Host Microbe. 2015 Oct 14;18(4):398-401
pubmed: 26468744
Int J Epidemiol. 2013 Aug;42(4):1002-11
pubmed: 24062286
Physica D. 2006 Mar 15;215(2):146-158
pubmed: 32287555
J R Soc Interface. 2008 Sep 6;5(26):1001-7
pubmed: 18319209
Epidemics. 2015 Mar;10:58-62
pubmed: 25843385
Clin Infect Dis. 2019 Oct 30;69(10):1780-1788
pubmed: 30689757
Am J Epidemiol. 2011 Dec 1;174(11):1246-55
pubmed: 22071585
Nature. 2006 Jul 27;442(7101):448-52
pubmed: 16642006
J R Soc Interface. 2005 Sep 22;2(4):295-307
pubmed: 16849187
PLoS One. 2016 Apr 21;11(4):e0153690
pubmed: 27100090
PLoS One. 2015 Sep 01;10(9):e0136497
pubmed: 26325289
Proc Biol Sci. 2014 Apr 30;281(1785):20140268
pubmed: 24789897
Am J Epidemiol. 1982 May;115(5):736-51
pubmed: 7081204
Stat Med. 2004 Nov 30;23(22):3469-87
pubmed: 15505892
Science. 2009 Oct 30;326(5953):729-33
pubmed: 19745114
PLoS One. 2014 Aug 15;9(8):e104786
pubmed: 25127257
Proc Biol Sci. 2010 Feb 22;277(1681):557-65
pubmed: 19864279
PLoS One. 2011 Feb 14;6(2):e16965
pubmed: 21347264
J R Soc Interface. 2009 Dec 6;6(41):1121-34
pubmed: 19324673
Vaccine. 2010 Mar 11;28(12):2370-84
pubmed: 20096762
Lancet Infect Dis. 2007 Apr;7(4):257-65
pubmed: 17376383
Am J Epidemiol. 2013 Dec 1;178(11):1655-62
pubmed: 24100954
BMC Infect Dis. 2009 Nov 27;9:187
pubmed: 19943919
PLoS One. 2014 Nov 25;9(11):e113711
pubmed: 25423343
Nature. 2004 May 13;429(6988):180-4
pubmed: 15141212
Ann Appl Stat. 2012 Mar;6(1):1-26
pubmed: 22639701
BMC Public Health. 2008 Feb 14;8:61
pubmed: 18275603
J Infect. 2008 Nov;57(5):361-73
pubmed: 18848358
Biostatistics. 2017 Apr 1;18(2):338-351
pubmed: 28025182
PLoS Comput Biol. 2010 Jan 29;6(1):e1000656
pubmed: 20126529
PLoS One. 2014 Sep 16;9(9):e107878
pubmed: 25226026
PLoS One. 2015 Mar 03;10(3):e0118457
pubmed: 25734772
Stat Med. 2018 Jun 30;37(14):2252-2266
pubmed: 29682776
BMC Infect Dis. 2014 Mar 10;14:136
pubmed: 24612900
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
J R Soc Interface. 2012 Nov 7;9(76):2826-33
pubmed: 22718990
BMC Infect Dis. 2015 Nov 02;15:494
pubmed: 26525046
EPJ Data Sci. 2016;5:21
pubmed: 27471661
PLoS One. 2017 Jan 18;12(1):e0170459
pubmed: 28099479
Biometrics. 1993 Dec;49(4):1099-109
pubmed: 8117903
Science. 2005 Aug 12;309(5737):1083-7
pubmed: 16079251
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5935-40
pubmed: 16585506
Am J Epidemiol. 2009 Sep 15;170(6):679-86
pubmed: 19679750
Nature. 2005 Sep 8;437(7056):209-14
pubmed: 16079797
Science. 2010 Nov 12;330(6006):982-5
pubmed: 21071671
PLoS One. 2011;6(8):e23176
pubmed: 21858018
PLoS One. 2015 Jul 15;10(7):e0133203
pubmed: 26176549
Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2825-30
pubmed: 21282645
PLoS One. 2014 Feb 05;9(2):e87042
pubmed: 24505274
PLoS One. 2014 Apr 25;9(4):e95978
pubmed: 24770359
J R Stat Soc Ser C Appl Stat. 2006 May;55(3):317-330
pubmed: 22457545
PLoS Comput Biol. 2012;8(9):e1002673
pubmed: 23028275
BMC Infect Dis. 2016 Jul 22;16:341
pubmed: 27449511
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252
PLoS One. 2012;7(10):e45113
pubmed: 23056193
Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4639-44
pubmed: 18332436
Lancet Infect Dis. 2009 May;9(5):291-300
pubmed: 19393959

Auteurs

Gail E Potter (GE)

The Emmes Company, Rockville, MD, United States of America.
California Polytechnic State University, San Luis Obispo, CA, United States of America.

Jimmy Wong (J)

California Polytechnic State University, San Luis Obispo, CA, United States of America.

Jonathan Sugimoto (J)

Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.

Aldiouma Diallo (A)

Institut de Recherche pour le Développement, Niakhar, Senegal.

John C Victor (JC)

PATH, Seattle, WA, United States of America.

Kathleen Neuzil (K)

University of Maryland Center for Vaccine Development, Baltimore, MD, United States of America.

M Elizabeth Halloran (ME)

Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Department of Biostatistics, University of Washington, Seattle, WA, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH